Haeun Yang (She/Her)

Ph.D. , Seoul National University
  • Korea (Republic of)

Intro Content

Clinical Epigenetics

Re-sensitizing CML to Imatinib: Dual Targeting of HDACs and BCR-ABL with Martinostat

Chronic Myeloid Leukemia (CML), driven by BCR-ABL, accounts for 15% of adult leukemias. While TKIs like imatinib improved outcomes, resistance remains a challenge. We demonstrate for the first time that the HDAC inhibitor martinostat shows potent activity in both TKI-sensitive and -resistant CML.

Topics

Channels contributed to:

Behind the Paper

Details

Online Elsewhere